NEOGENOMICS INC — Director's Dealing 2019

Mar 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2019-03-01

Reporting Person: VAN OORT DOUGLAS M (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-01	Common Stock	A	37883	—	Acquired	2092435	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-01	Stock Option (Right to Buy)	$19.6	A	231567	Acquired	2024-03-01	Common Stock (231567.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	187500	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (500000.0)	500000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (500000.0)	500000	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (472527.0)	472527	Direct

Footnotes

F1: Conundrum Capital Partners, LLC is a limited liability partnership 50% owned by Mr. VanOort. Mr.VanOort is a managing partner of Conundrum Capital Partners, LLC.

F2: On March 1, 2019, Mr. VanOort was granted an option to purchase 231,567 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.

F3: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F5: On April 20, 2016, Mr. VanOort was granted 472,527 stock options. These options vest ratably over the first three anniversary dates of the grant date.